Application of reasonable antiviral treatment of chronic hepatitis B in implementation of treatment goals in the guidelines

doi:10.3877/cma.j.issn.1674-1358.2018.01.004

Abstract

Abstract:

How to choose and use interferon (IFN) and nucleoside analogues (NAs) to achieve the chronic hepatitis B the treatment goals, and the mechanism and characteristics of the two kinds of drugs were investigated. In order to gradually achieve the satisfied even the ideal milestone, it needs combination and sequential application of interferon therapy at the right time through evaluating and monitoring the changes of HBsAg and HBeAg quantity. Reasonable antiviral therapy could improve the efficacy of chronic hepatitis B to the maximum extent.

Key words: Chronic hepatitis B, Sequential therapy, Combined therapy, Antiviral therapy

Yuanshan Zhang. Application of reasonable antiviral treatment of chronic hepatitis B in implementation of treatment goals in the guidelines[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(01): 15-19.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2018.01.004

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2018/V12/I01/15

References 48

[1]	European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection[J]. J Hepatol,2012,57(1):167-185.
[2]	Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J]. Hepatol Int,2016,10(1):1-98.
[3]	中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 中华肝脏病杂志,2015,23(12):888-905.
[4]	Martin P, Lau DTY, Nguyen MH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 Update[J]. Clin Hepatol Gas,2015,13(12):2071-2087(e16).
[5]	Wang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response[J]. World J Gastroenterol,2014,20(23):7207-7212.
[6]	Wang FS, Zhang Z. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus[J]. Expert Rev Gas,2009,3(5):499-512.
[7]	Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment[J]. Liver Int,2009,29(1):100-107.
[8]	Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels[J]. Am J Med,2004,116(12):829-834.
[9]	Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma[J]. J Hepatol,2007,46(1):45-52.
[10]	Sarri G, Westby M, Bermingham S, et al. Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance[J]. BMJ,2013,347(7915):31-33.
[11]	Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection[J]. J Hepatol,2010,52(6):791-799.
[12]	Güzelbulut F, Ovünç AO, Oetinkaya ZA, et al. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B[J]. Hepato Gastroenterology,2012,59(114):477-480.
[13]	Sonneveld MJ, Zoutendijk R, Hansen BE, et al. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir[J]. Antivir Ther,2012,17(8):1605-1608.
[14]	Mao Q, Zhang HY, You JP, et al. Severe acute exacerbation of chronic hepatitis B during pegylated interferon treatment and early intervention with corticosteroid[J]. Virol J,2012,9:136.
[15]	Seto WK, Hui AJ, Wong VWS, et al. Original article:treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study[J]. Gut,2015,64(4):667-672.
[16]	Chi H, Hansen BE, Yim C, et al. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B[J]. Aliment Pharmacol Ther,2015,41(9):867-876.
[17]	Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients[J]. Hepatol Int,2013,7(1):88-97.
[18]	Buster EHCJ, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b[J]. Gastroenterology,2008,135(2): 459-467.
[19]	Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy[J]. Antivir Ther,2011,16(5):629-637.
[20]	Strassburg CP. What is the influence of genotype on the success of treatment for chronic hepatitis B? Nature clinical practice[J]. Gastroen Hepatol,2006,3(11):620-621.
[21]	Mao QG, Pan JS, Fang KN, et al. Precise prediction model and simplified scoring system for sustained combined response to interferon-alpha[J]. World J Gastroenterol,2010,16(27):3465-3471.
[22]	Carlo F. HBV and the immune response[J]. Liver Int,2015,35(1):121-128.
[23]	Reignat S, Webster GJM, Brown D, et al. Escaping high viral load exhaustion[J]. J Exp Med,2002,195(9):1089-1101.
[24]	Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues[J]. Gastroenterology,2012,143(4):963-973(e9).
[25]	Boglione L, D’Avolio A, Cariti G, et al. Sequential therapy with entecavir and PegINF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes[J]. Viral Hepat,2013,20(4):11-19.
[26]	Okuse C, Yotsuyanagi H, Yamada N, et al. Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B[J]. Hepatol Res,2010,40(5):461-469.
[27]	Piccolo P, Lenci I, Paolo D, et al. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B[J]. Antivir Ther,2013,18(1):57-64.
[28]	Sarin SK, Kumar M, Kumar R, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients[J]. Am J Gastroenterol,2005,100(11):2463-2471.
[29]	Annikki N, Femke S, Louis J, et al. Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy[J]. J Hepatol,2016,64(3):539-546.
[30]	Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J]. New Engl J Med,2005,352(26):2682-2695.
[31]	Marcellin P, Lau KKG, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-Negative chronic hepatitis B[J]. New Engl J Med,2004,351(12):1206-1217.
[32]	Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group[J]. New Engl J Med,1998,339(2):61-68.
[33]	Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase[J]. Gut,2003,52(3):420-424.
[34]	Eric H, Buster CJ, Hansen BE, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa[J]. Gastroenterology,2009,137(6):2002-2009.
[35]	Boglione, Cariti G, Di PG, et al. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B[J]. J Med Virol,2016,88(11):1953-1959.
[36]	Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)[J]. J Hepatol,2014,61(4):777-784.
[37]	Caruntu FA, Curescu M, Olaru I, et al. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study[J]. Gastrointestin Liver Dis,2013,22(1):27-32.
[38]	Peng H, Wei F, Liu JY, et al. Response-guided therapy of regimens based on Peg-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis[J]. Hepatol Int,2015,9(4):543-557.
[39]	Moucari R, Boyer N, Ripault MP, et al. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients[J]. J Viral Hepatitis,2011,18(8):580-586.
[40]	Li GJ, Yu YQ, Chen SL, et al. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment[J]. Antimicrob Agents Chemother,2015,59(7):4121-4128.
[41]	Matsumoto A, Yatsuhashi H, Nagaoka S, et al. Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B[J]. Hepatol Res,2015,45(12):1195-1202.
[42]	Suzuki F, Arase Y, Suzuki Y, et al. Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan[J]. J Gastroenterology,2012,47(7):814-822.
[43]	Michelle MP, Tarik A, Patrick M. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients[J]. Liver Int,2015,35(1):82-90.
[44]	纪永健，李菲菲，任万华, 等. HBeAg早期下降对聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎的疗效预测[J]. 中华肝脏病杂志,2013,21(5):335-339.
[45]	Chen GY, Zhu MF, Zheng DL, et al. Baseline HBsAg predicts response to pegylated interferon-α-2b in HBeAg-positive chronic hepatitis B patients[J]. World J Gastroenterol,2014,20(25):8195-8200.
[46]	Milan JS, Vincent R, Charles ABB, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline[J]. Hepatology,2010,52(4):1251-1257.
[47]	Fan R, Sun J, Yuan Q, et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleoside analogues[J]. Gut,2016,65(2):313-320.
[48]	于海滨，玛丽娜，柳雅立, 等. 非活动性HBsAg携带者聚乙二醇干扰素α-2a治疗过程中CD8⁺38⁺/CD8⁺变化及其临床意义[J]. 中华肝脏病杂志,2013,21(12):895-898.

Please choose a citation manager

Content to export